Reply: In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
2008
Reply on Anticancer Efficacy of Anti-CEA Antibodies
publication
Evidence: moderate
Author Information
Author(s): Ashraf S Q, Conaghan P J, Wilding J L, Bodmer W F
Primary Institution: Weatherall Institute of Molecular Medicine, University of Oxford
Hypothesis
Are there any unconjugated antibodies to carcinoembryonic antigen (CEA) being used for colorectal cancer treatment?
Conclusion
No unconjugated antibody targeting CEA has been licensed for colorectal cancer treatment in humans.
Supporting Evidence
- The authors clarify that their original statement about the lack of unconjugated antibodies for CEA treatment still holds true.
- They mention that while there are many antibodies under clinical testing, none targeting CEA are licensed for use.
- The study highlights the importance of immune-mediated responses in cancer treatment.
Takeaway
The study says that there are no approved naked antibodies for treating colorectal cancer that target CEA, despite some claims to the contrary.
Limitations
The study acknowledges that xenograft models may not accurately reflect human antibody efficacy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website